Sciegen Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SCIEGEN PHARMS
SCIEGEN PHARMS has one hundred and eleven approved drugs.
Drugs and US Patents for Sciegen Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sciegen Pharms | FEXOFENADINE HYDROCHLORIDE HIVES | fexofenadine hydrochloride | TABLET;ORAL | 204507-004 | Sep 16, 2015 | OTC | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Sciegen Pharms | LEVOCETIRIZINE DIHYDROCHLORIDE | levocetirizine dihydrochloride | TABLET;ORAL | 203646-001 | Sep 9, 2014 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Sciegen Pharms | QUETIAPINE FUMARATE | quetiapine fumarate | TABLET;ORAL | 090960-003 | Mar 27, 2012 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Sciegen Pharms | LAMOTRIGINE | lamotrigine | TABLET, EXTENDED RELEASE;ORAL | 202498-004 | Jan 4, 2013 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Sciegen Pharms | ATORVASTATIN CALCIUM | atorvastatin calcium | TABLET;ORAL | 205519-004 | May 19, 2016 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Sciegen Pharms | RELGAABI | gabapentin | CAPSULE;ORAL | 204989-002 | Feb 18, 2016 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

